GELESIS HOLDINGS, INC.
DelistedCIK 1805087fmd_1QBYVP02S7BJZB4JB0DKNXH4DQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 02, 2020 to Jun 30, 2023, 13 periods
| Line item | FY2021 | FY2022 |
|---|---|---|
| Total revenues | 11 | 26 |
| Cost of revenue | 10 | 28 |
| Gross profit | 1 | (2) |
| Research and development | 13 | 19 |
| Selling, general and administrative | 71 | 99 |
| Operating income | (85) | (122) |
| Interest expense | 1 | 1 |
| Interest and investment income | 0 | – |
| Other non-operating income (expense) | 1 | 5 |
| Income before taxes | (93) | (55) |
| Income tax expense | 0 | 0 |
| Net income from continuing operations | (93) | (56) |
| Net income | (93) | (56) |
| Net income to common shareholders | (188) | (95) |